Understand the source comparison
Spadin Analog Research: Comparison Table
Before selecting a Spadin analog variant, researchers should understand how structural modifications affect experimental utility, bioavailability, and receptor selectivity. The table below compares three common Spadin analog modification strategies across key
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a Spadin analog variant, researchers should understand how structural modifications affect experimental utility, bioavailability, and receptor selectivity. The table below compares three common Spadin analog modification strategies across key research parameters.
- | Analog Type | Primary Modification | TREK-1 Binding Affinity (IC50) | Serum Half-Life | BBB Penetration (%) | Ideal Application | Professional Assessment ||—|—|—|—|—|—|| Native Spadin Sequence | None (17-AA GKKPYRWGTKIVHQWYC) | 10–20 nM | <5 minutes | <2% | In vitro slice electrophysiology, direct CNS injection studies | Highest receptor affinity but impractical for systemic administration. Use when BBB penetration is not required || N-Acetylated Analog | Acetyl group at N-terminus | 15–35 nM | 20–40 minutes | 8–15% | Behavioral stress models, chronic peripheral dosing protocols | Best balance of stability and CNS access for in vivo work. Slight affinity reduction acceptable given extended half-life || C-Terminal Serine Substitution | Cysteine-17 replaced with serine | 25–50 nM | 15–25 minutes | 5–10% | Long-term storage stability studies, multi-dose experiments | Prevents dimerization during storage. Lower affinity tolerable when using higher concentrations || Dual-Modified (N-Acety